02:36 , Mar 3, 2017 |  BC Week In Review  |  Clinical News

NA-1: Ph III ESCAPE-NA-1 started

NoNo began the double-blind, placebo-controlled, international Phase III ESCAPE-NA-1 trial to evaluate 2.6 mg/kg IV NA-1 in about 1,120 patients who are candidates for endovascular revascularization. NoNo Inc. , Toronto, Ontario  Product: NA-1   Business:...
08:00 , Mar 3, 2016 |  BC Innovations  |  Targets & Mechanisms

Rescue mission

A pair of preclinical studies published last month on the autism target SHANK3 provide what might be the most meaningful progress for patients since the gene was linked with the disease over a decade ago....
08:00 , Jan 20, 2014 |  BioCentury  |  Emerging Company Profile

Zocere: Stepping up in stroke

Zocere Inc. may have found a new way to decrease ischemic brain injury in patients following stroke. The company is developing an injectable, degradation-resistant version of the neuroprotective STEP protein that could improve patient outcomes...
07:00 , Apr 29, 2013 |  BioCentury  |  Emerging Company Profile

Avilex: One-two pain punch

Avilex Pharma ApS may have found a way to block activation of the NMDA receptor pathway to treat chronic pain and ischemic stroke. Rather than directly hitting the receptor itself, the approach targets a downstream...
00:11 , Apr 17, 2013 |  BC Extra  |  Financial News

Avilex debuts to develop compounds for neuropathic pain

Avilex Pharma ApS (Copenhagen, Denmark) debuted with undisclosed seed funding from Novo Seeds to develop small molecule ligands targeting discs large homolog 4 ( DLG4 ; PSD95 ) for neurology indications. Avilex's lead compounds --...
07:00 , Mar 22, 2012 |  BC Innovations  |  Tools & Techniques

Monkeys bridge the stroke gap

Toronto-based NoNO Inc. has become the first company to show that macaque models have the potential to derisk clinical testing of new stroke therapies, which typically have gone right from rat or rabbit models into...
08:00 , Mar 8, 2012 |  BC Innovations  |  Distillery Techniques

Technology: Disease models

Approach Summary Licensing status Publication and contact information Disease models Neuroprotection and functional recovery in macaque models of stroke Macaque models could aid the development of neuroprotective therapies to treat stroke. In macaque models of...
08:00 , Mar 1, 2012 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Stroke Discs large homolog 4 (DLG4; PSD95) Mouse studies identified a peptide-based PSD95 inhibitor that could help treat stroke. PSD95 inhibitors containing two distinct PSD95-binding...
08:00 , Dec 9, 2010 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Stroke Discs large homolog 4 (DLG4; PSD95); neuronal nitric oxide synthase 1 (NOS1; nNOS) Rodent studies suggest that inhibiting interactions between nNOS and PSD95 in...
08:00 , Dec 18, 2008 |  BC Innovations  |  Cover Story

Uncoupling pain from the psyche

University of Toronto researchers have reported a way to block pain-induced activation of neuronal receptors while preserving their basic functions. 1 The strategy could avoid the psychomotor side effects associated with centrally acting chronic pain...